Abstract

BackgroundExtralevator abdominoperineal excision (ELAPE), abdominoperineal excision (APE) or pelvic exenteration (PE) with or without sacral resection (SR) for locally advanced rectal cancer leaves a significant defect in the pelvic floor. At first, this defect was closed primarily. To prevent perineal hernias, the use of a biological mesh to restore the pelvic floor has been increasing. The aim of this study, was to evaluate the outcome of the use of a biological mesh after ELAPE, APE or PE with/without SR.MethodsA retrospective study was conducted on patients who had ELAPE, APE or PE with/without SR with a biological mesh (Permacol™) for pelvic reconstruction in rectal cancer in our center between January 2012 and April 2015. The endpoints were the incidence of perineal herniation and wound healing complications.ResultsData of 35 consecutive patients [22 men, 13 women; mean age 62 years (range 31–77 years)] were reviewed. Median follow-up was 24 months (range 0.4–64 months). Perineal hernia was reported in 3 patients (8.6%), and was asymptomatic in 2 of them. The perineal wound healed within 3 months in 37.1% (n = 13), within 6 months in 51.4% (n = 18) and within 1 year in 62.9% (n = 22). In 17.1% (n = 6), the wound healed after 1 year. It was not possible to confirm perineal wound healing in the remaining 7 patients (20.0%) due to death or loss to follow-up. Wound dehiscence was reported in 18 patients (51.4%), 9 of whom needed vacuum-assisted closure therapy, surgical closure or a flap reconstruction.ConclusionsClosure of the perineal wound after (EL)APE with a biological mesh is associated with a low incidence of perineal hernia. Wound healing complications in this high-risk group of patients are comparable to those reported in the literature.

Highlights

  • Abdominoperineal excision (APE) is widely used in the treatment of rectal cancer when the tumour is less than 6 cm from the anal verge

  • We describe our results with an emphasis on perineal hernia and wound healing

  • Almost all patients had resection for a primary or recurrent rectal adenocarcinoma; one patient was treated for a rectal gastrointestinal stromal tumour (GIST)

Read more

Summary

Introduction

Abdominoperineal excision (APE) is widely used in the treatment of rectal cancer when the tumour is less than 6 cm from the anal verge. Extralevator abdominoperineal excision (ELAPE), abdominoperineal excision (APE) or pelvic exenteration (PE) with or without sacral resection (SR) for locally advanced rectal cancer leaves a significant defect in the pelvic floor. At first, this defect was closed primarily. The use of a biological mesh to restore the pelvic floor has been increasing. Methods A retrospective study was conducted on patients who had ELAPE, APE or PE with/without SR with a biological mesh (PermacolTM) for pelvic reconstruction in rectal cancer in our center between January 2012 and April 2015. It was not possible to confirm perineal wound healing in the remaining 7 patients (20.0%) due to death or loss to follow-up. Wound healing complications in this high-risk group of patients are comparable to those reported in the literature

Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call